Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Merck Millipore Adds Human Recombinant ATM Enzyme to Kinase Enzyme Portfolio

publication date: Sep 18, 2013
 | 
author/source: Feinstein Kean Healthcare

Merck Millipore Adds Human Recombinant Ataxia Telangiectasia Mutated (ATM) Enzyme to Comprehensive Kinase Enzyme Portfolio

  • Human KinomeATM plays a key role in events following DNA damage and, as such, is an important drug target
  • Recombinantly expressed ATM available at pharmaceutical-grade yield, purity and activity
  • Part of the 400+ Upstate® enzyme portfolio and the KinaseProfiler™ fee-for-service testing panel

Merck Millipore, the Life Science division of Merck, has added the ataxia telangiectasia mutated (ATM) enzyme to its extensive kinase enzyme portfolio. ATM is now part of the Upstate® portfolio offered by the company that includes more than 400 kinase and phosphatase enzymes and the KinaseProfile™ fee-for-service testing panel.

Because it is a master regulator of cell death after DNA damage, the ATM enzyme is of high interest to pharmaceutical and biotechnology companies as a drug target. ATM-inhibited cells have increased sensitivity to radiation, so drugs blocking the enzyme may improve the effectiveness of radiation therapy for cancer. ATM also plays a critical role in neuron death, so ATM inhibitors are being studied for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

Merck Millipore produces this important enzyme using a biomanufacturing process based on a mammalian host cell system that yields the full-length ATM enzyme at high purity and activity.  This process overcomes the difficulties faced to date in producing large quantities of the enzyme.

"The development of human ATM enzyme at a manufacturing scale with purity and activity that meet the needs of the pharmaceutical industry is a breakthrough," notes Steve Davies, Director of Merck Millipore's Discovery and Development Solutions business at Dundee, Scotland. "Through the innovations of our protein production and biochemical assay development groups, this product and accompanying protocols remove a major hurdle for companies developing drugs against this target."

Data accompanying Merck Millipore's ATM enzyme demonstrating enzyme activity and selective inhibition by tool compounds qualify its use in drug discovery applications and enable scientists to readily incorporate the enzyme into their in-house testing.


more about Kinases


more about Merck Millipore


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events